Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Share-based Compensation of $686000.0 in Q1 2026, up 257.29% quarter-over-quarter from $192000.0 in Q4 2025, and up 46.58% on a YoY basis from $468000.0 in Q1 2025.
Galectin Therapeutics (GALT) Share-based Compensation (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $686000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 46.58% year-over-year to $686000.0; the TTM figure through Mar 2026 stood at $1.9 million (down 33.62% YoY), while the FY2025 annual figure was $1.7 million, down 32.33% from the prior year.
- Share-based Compensation was $686000.0 for Q1 2026 at Galectin Therapeutics, up from $192000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q4 2024 to a low of $192000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $613764.7 across 5 years, with a median of $604000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 2351.43% in 2022, then tumbled 82.62% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $681000.0 in 2022, then dropped by 27.02% to $497000.0 in 2023, then jumped by 122.33% to $1.1 million in 2024, then sank by 82.62% to $192000.0 in 2025, then jumped by 257.29% to $686000.0 in 2026.
- The last three Share-based Compensation figures came in at $686000.0 (Q1 2026), $192000.0 (Q4 2025), and $498000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | 686,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 686,000.00 |
| Mar 31, 2026 | 686,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 515,000.00 |
| Sep 30, 2024 | 515,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Jun 30, 2024 | 738,000.00 |
| Mar 31, 2024 | 604,000.00 |
| Mar 31, 2024 | 604,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Dec 31, 2023 | 497,000.00 |